A lipid profile of blood plasm inpatients with metabolic syndrome and manifest disorder ofcarbohydrate metabolism


Aim. To study specific features of lipid plasm profile in patients with metabolic syndrome (MS) and
manifest disorder of carbohydrate metabolism (CM) as well as their relationships with clinical symptoms of MS.
Materials and methods. Contents of lipids and apolipoproteins of plasm was measured on an empty
stomach in 30 patients (18 females and 12 males) with MS and manifest disorder of CM (diabetes
mellitus type 2 at the stage of good and satisfactory compensation of CM without terminal complications).
Results. The patients were found to have a subnormal level of HDLP cholesterol, high levels of total
cholesterol, LDLP cholesterol and LPa. Hypertriglyceridemia occurred only in 31.4% patients
(TG < 200 mg/dl). Mean TG level was 173.69 ± 27.52 mg/dl. TG and diastolic arterial pressure,
fasting glycemia and waist circumference significantly correlated. If the WC/TC was 1.0 and higher,

И. В.
the antiatherogenic plasm factor ~ HDLP cholesterol - significantly lowered. Positive correlation existed between TG and total cholesterol, LDLP cholesterol, apoB, LDLP cholesterol/'HDLP cholester-
ol, apoB/apoAl, while negative correlation was seen between TG and HDLP cholesterol levels. Patients with hypertriglyceridemia had significantly higher levels of total cholesterol, LDLP cholesterol,
apoB, apoB/apoAl.
Conclusion. Plasm levels of TG most significantly reflect severity of basic clinical manifestations of
MS: abdominal obesity, arterial hypertension, CM compensation. The presence of hypertriglyceridemia in MS patients can be considered as an indicator of high atherogenic potential of plasm.


  1. Зимин Ю. В. Кардиология 1998; 6: 71-81.
  2. Reaven G. Physiol. Rev. 1995; 1: 473-486.
  3. Reaven G. Diabetes 1988; 37: 1595-1607.
  4. Despres G., Lamarche В., Cantin B. et al. N. Engl. J. Med. 1996; 334: 952-957.
  5. Bonora £., Kiechl S., Willeit J. et al. Diabetes 1998; 47(10): 1643-1649.
  6. De Fronso R. Neth. J. Med. 1997; 1 (5): 191-197.
  7. Ferrannini E., Camastra S. Eur. J. Clin. Invest. 1998; 1: 2-7.
  8. Fontbonne A. Diabetes Metab. 1996; 1: 305-313 .
  9. Шестакова М. В. Тер. арх. 1999; 1: 39-41.
  10. Haffner S., Mykkanen L., Hales С N. et al. Stroke 1998; 1 (8): 1498-1503.
  11. Haffner S., Valdez R., Hazuda H. et al. Diabetes 1992; 41: 715-722 .
  12. Hamsten A., Carpe F. In: Lipids and lipoproteins. New York: Martin Dunitz LTD; 1996. 110-114.
  13. Laakso M. Diabetes Rev. 1995; 3: 408-422.
  14. Assmann G, Schulte H. Am. Heart J. 1988; 116: 1713-1724.
  15. Grundy S. Am. J. Cardiol. 1998; 81 (4): 18-25.
  16. Seed M. In: Lipids and lipoproteins. New York: Martin Dunitz LTD; 1996. 115-143.



Abstract - 117


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2003 Medvedeva I.V., Dorodneva E.F., Pugacheva T.A., Bekhikova L.N., Zhuravleva T.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies